Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis
Amyloidosis aims
Free light chain (FLCs)
Hematologic responses (hemCR)
Issue Date: 
Springer Nature
info:eu-repo/grantAgreement/MINECO/Proyectos de investigación en salud (AE en Salud)/PI13/ 02196/ES/Caracterización fenotípica y molecular de la amiloidosis primaria: implicaciones en las manifestaciones clínicas y pronóstico de la enfermedad
s This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Kastritis, E. (Efstathios); Kostopoulos, I.V. (Ioannis V.); Terpos, E. (Evangelos); et al. "Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis". Blood cancer journal. 8 (46), 2018,
The treatment of light chain (AL) amyloidosis aims to completely eliminate the toxic light chain production, as assessed by sensitive serum- or urine-based methods such as immunofixation and free light chain (FLCs) quantification. Complete hematologic responses (hemCR) can be achieved in a significant proportion of patients with AL, either with conventional therapies or with high-dose melphalan, and are associated with better overall survival and improved organ function. However, hematologic relapses still occur and organ function may continue to deteriorate due to small residual clones that may lead to disease recurrence and/or may produce very small amounts of toxic light chains which are undetectable by conventional techniques. Next-generation flow cytometry (NGF) is a very sensitive method for the evaluation of minimal residual disease (MRD) and one of the standard methods for the assessment of MRD in patients with multiple myeloma (MM), reflected in the new response assessment criteria2. Patients with MM who are negative for MRD have significantly improved progression-free and overall survival, even among those who have achieved a CR3,4. Such data are sparse in patients with AL amyloidosis, although the presence of MRD may prove a crucial factor for delayed organ response or deterioration of organ function despite conventional hemCR. The aim of the current study was to evaluate feasibility and applicability of MRD by NGF in patients with AL at hemCR.

Files in This Item:
385.48 kB
Adobe PDF

Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.